Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • TA178
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence